VSAR - Versartis, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Versartis, Inc.

1020 Marsh Road
Menlo Park, CA 94025
United States
650-963-8580
http://www.versartis.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees10

Key Executives

NameTitlePayExercisedYear Born
Mr. Jay P. ShepardPres, CEO & Director866.41kN/A1958
Ms. Tracy M. WoodyChief Commercial OfficerN/AN/A1970
Dr. Jeffrey L. ClelandCo-FounderN/AN/A1965
Dr. Joshua Silverman Ph.D.Co-FounderN/AN/AN/A
Mr. Kevin HaasVP of Fin.N/AN/A1965
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Versartis, Inc. operates as an endocrine-focused biopharmaceutical company in the United States. It is developing somavaratan, a long-acting recombinant human growth hormone for the treatment of growth hormone deficiency. The company was founded in 2008 and is headquartered in Menlo Park, California.

Corporate Governance

Versartis, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.